CRL logo

CRL Cash And Cash Equivalents

CRL Annual Cash & Cash Equivalents

$276.77 M
+$42.86 M+18.32%

30 December 2023

CRL Cash And Cash Equivalents Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

CRL Quarterly Cash And Cash Equivalents

$210.17 M
+$30.96 M+17.27%

28 September 2024

CRL Quarterly Cash And Cash Equivalents Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

CRL Cash And Cash Equivalents Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+18.3%-24.1%
3 y3 years+21.2%-24.1%
5 y5 years+41.6%-24.1%

CRL Cash And Cash Equivalents High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+18.3%-35.7%+33.7%
5 y5-yearat high+21.2%-54.8%+33.7%
alltimeall timeat high+1743.9%-54.8%+1038.6%

Charles River Laboratories International Cash And Cash Equivalents History

DateAnnualQuarterly
Sept 2024
-
$210.17 M(+17.3%)
June 2024
-
$179.21 M(-45.2%)
Mar 2024
-
$327.04 M(+18.2%)
Dec 2023
$276.77 M(+18.3%)
$276.77 M(+76.1%)
Sept 2023
-
$157.17 M(-21.6%)
June 2023
-
$200.44 M(-0.6%)
Mar 2023
-
$201.59 M(-13.8%)
Dec 2022
$233.91 M(-3.0%)
$233.91 M(+20.8%)
Sept 2022
-
$193.70 M(-3.3%)
June 2022
-
$200.32 M(-17.2%)
Mar 2022
-
$241.87 M(+0.3%)
Dec 2021
$241.21 M(+5.6%)
$241.21 M(+13.5%)
Sept 2021
-
$212.54 M(-4.7%)
June 2021
-
$222.97 M(-52.1%)
Mar 2021
-
$465.41 M(+103.7%)
Dec 2020
$228.42 M(-4.0%)
$228.42 M(-6.0%)
Sept 2020
-
$242.88 M(-39.6%)
June 2020
-
$402.02 M(+7.9%)
Mar 2020
-
$372.43 M(+56.5%)
Dec 2019
$238.01 M(+21.8%)
$238.01 M(+44.5%)
Sept 2019
-
$164.76 M(-17.9%)
June 2019
-
$200.59 M(+58.8%)
Mar 2019
-
$126.32 M(-35.4%)
Dec 2018
$195.44 M(+19.3%)
$195.44 M(+40.7%)
Sept 2018
-
$138.87 M(-27.8%)
June 2018
-
$192.30 M(+2.4%)
Mar 2018
-
$187.77 M(+14.6%)
Dec 2017
$163.79 M(+39.2%)
$163.79 M(+32.5%)
Sept 2017
-
$123.62 M(+6.1%)
June 2017
-
$116.47 M(-11.4%)
Mar 2017
-
$131.52 M(+11.8%)
Dec 2016
$117.63 M(-0.3%)
$117.63 M(+11.3%)
Sept 2016
-
$105.72 M(-31.6%)
June 2016
-
$154.59 M(-1.8%)
Mar 2016
-
$157.38 M(+33.4%)
Dec 2015
$117.95 M(-26.3%)
$117.95 M(+59.3%)
Sept 2015
-
$74.03 M(-50.9%)
June 2015
-
$150.81 M(-0.7%)
Mar 2015
-
$151.92 M(-5.1%)
Dec 2014
$160.02 M(+2.6%)
$160.02 M(+22.4%)
Sept 2014
-
$130.75 M(+11.7%)
June 2014
-
$117.01 M(-31.1%)
Mar 2014
-
$169.85 M(+8.9%)
Dec 2013
$155.93 M(+42.2%)
$155.93 M(+19.5%)
Sept 2013
-
$130.45 M(+14.9%)
June 2013
-
$113.52 M(+13.0%)
Mar 2013
-
$100.42 M(-8.4%)
Dec 2012
$109.69 M
$109.69 M(+31.8%)
Sept 2012
-
$83.22 M(+9.4%)
June 2012
-
$76.08 M(+24.7%)
DateAnnualQuarterly
Mar 2012
-
$61.03 M(-11.4%)
Dec 2011
$68.91 M(-61.5%)
$68.91 M(-15.2%)
Sept 2011
-
$81.22 M(-44.3%)
June 2011
-
$145.83 M(-8.1%)
Mar 2011
-
$158.75 M(-11.4%)
Dec 2010
$179.16 M(-1.9%)
$179.16 M(+30.4%)
Sept 2010
-
$137.43 M(-37.3%)
June 2010
-
$219.08 M(-1.4%)
Mar 2010
-
$222.20 M(+21.7%)
Dec 2009
$182.57 M(-25.0%)
$182.57 M(-5.0%)
Sept 2009
-
$192.20 M(+24.2%)
June 2009
-
$154.81 M(-9.1%)
Mar 2009
-
$170.23 M(-30.1%)
Dec 2008
$243.59 M(+8.0%)
$243.59 M(+14.4%)
Sept 2008
-
$212.85 M(-18.9%)
June 2008
-
$262.44 M(+9.4%)
Mar 2008
-
$239.88 M(+6.4%)
Dec 2007
$225.45 M(+28.5%)
$225.45 M(+22.9%)
Sept 2007
-
$183.50 M(+13.2%)
June 2007
-
$162.05 M(+18.7%)
Mar 2007
-
$136.54 M(-22.1%)
Dec 2006
$175.38 M(+52.7%)
$175.38 M(-30.8%)
Sept 2006
-
$253.50 M(+31.3%)
June 2006
-
$193.07 M(+90.3%)
Mar 2006
-
$101.46 M(-11.6%)
Dec 2005
$114.82 M(-44.7%)
$114.82 M(-31.5%)
Sept 2005
-
$167.71 M(+0.7%)
June 2005
-
$166.55 M(-21.8%)
Mar 2005
-
$213.06 M(+2.6%)
Dec 2004
$207.57 M(+13.8%)
$207.57 M(-20.0%)
Sept 2004
-
$259.41 M(+15.7%)
June 2004
-
$224.15 M(+18.1%)
Mar 2004
-
$189.75 M(+4.1%)
Dec 2003
$182.33 M(+48.8%)
$182.33 M(+11.0%)
Sept 2003
-
$164.32 M(+13.8%)
June 2003
-
$144.34 M(+26.6%)
Mar 2003
-
$114.01 M(-6.9%)
Dec 2002
$122.51 M(+110.2%)
$122.51 M(+9.0%)
Sept 2002
-
$112.39 M(+32.7%)
June 2002
-
$84.71 M(-37.4%)
Mar 2002
-
$135.40 M(+132.4%)
Dec 2001
$58.27 M(+75.9%)
$58.27 M(-25.6%)
Sept 2001
-
$78.30 M(+175.6%)
June 2001
-
$28.42 M(-60.8%)
Mar 2001
-
$72.40 M(+118.5%)
Dec 2000
$33.13 M(+120.7%)
$33.13 M(+18.3%)
Sept 2000
-
$28.01 M(+47.5%)
June 2000
-
$18.99 M(+2.9%)
Mar 2000
-
$18.46 M
Dec 1999
$15.01 M(-39.5%)
-
Dec 1998
$24.81 M
-

FAQ

  • What is Charles River Laboratories International annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Charles River Laboratories International?
  • What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?
  • What is Charles River Laboratories International quarterly cash and cash equivalents?
  • What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?
  • What is Charles River Laboratories International quarterly cash and cash equivalents year-on-year change?

What is Charles River Laboratories International annual cash & cash equivalents?

The current annual cash & cash equivalents of CRL is $276.77 M

What is the all time high annual cash & cash equivalents for Charles River Laboratories International?

Charles River Laboratories International all-time high annual cash & cash equivalents is $276.77 M

What is Charles River Laboratories International annual cash & cash equivalents year-on-year change?

Over the past year, CRL annual cash & cash equivalents has changed by +$42.86 M (+18.32%)

What is Charles River Laboratories International quarterly cash and cash equivalents?

The current quarterly cash and cash equivalents of CRL is $210.17 M

What is the all time high quarterly cash and cash equivalents for Charles River Laboratories International?

Charles River Laboratories International all-time high quarterly cash and cash equivalents is $465.41 M

What is Charles River Laboratories International quarterly cash and cash equivalents year-on-year change?

Over the past year, CRL quarterly cash and cash equivalents has changed by -$66.60 M (-24.06%)